title: Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.
abstract: The circulating cytokine concentrations following administration of subcutaneous recombinant interleukin 2 (IL-2) in combination with interferon alpha and 5-fluorouracil used to treat advanced renal cancer were studied. One patient was anephric and on dialysis, and seven had normal biochemical renal function, although five had undergone single nephrectomy. The pharmacokinetics of IL-2 and changes in IL-6 and tumour necrosis factor (TNF)-alpha were essentially similar in all patients including the anephric patient, irrespective of the periods of dialysis, although at some time points, IL-2 concentrations were slightly higher in the anephric patient than in the others. These results show that for subcutaneous administration of low-dose IL-2, renal clearance of IL-2 is not important. This contrasts with high-dose, intravenous IL-2 where blood concentrations are higher and renal clearance seems to occur, perhaps because of saturation of the non-renal mechanisms of clearance. The subcutaneous route is certainly preferred if IL-2 is used in anephric patients and in those with impaired renal function, and it may be generally preferred for most purposes.
authors.affiliation: Imperial Cancer Research Fund Cancer Medicine Research Unit, St James's University Hospital, Leeds, UK.
authors.forename: R E
authors.initials: RE
authors.lastname: Banks
authors.forename: M A
authors.initials: MA
authors.lastname: Forbes
authors.forename: S
authors.initials: S
authors.lastname: Hallam
authors.forename: A
authors.initials: A
authors.lastname: Jenkins
authors.forename: M
authors.initials: M
authors.lastname: Wadhwa
authors.forename: P
authors.initials: P
authors.lastname: Dilger
authors.forename: A
authors.initials: A
authors.lastname: Meager
authors.forename: R
authors.initials: R
authors.lastname: Thorpe
authors.forename: C J
authors.initials: CJ
authors.lastname: Bowmer
authors.forename: J K
authors.initials: JK
authors.lastname: Joffe
authors.forename: P
authors.initials: P
authors.lastname: Patel
authors.forename: P W
authors.initials: PW
authors.lastname: Johnson
authors.forename: P J
authors.initials: PJ
authors.lastname: Selby
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001681:Biological Assay; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000628:therapy*; D016207:Cytokines / Q000097:blood / Q000378:metabolism*; D003627:Data Interpretation, Statistical; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007118:Immunoassay; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000097:blood; D007668:Kidney / Q000378:metabolism; D007680:Kidney Neoplasms / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D013997:Time Factors
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D016207:Cytokines; D016898:Interferon-alpha; D007376:Interleukin-2; D005472:Fluorouracil